Latest Insider Transactions at Sarepta Therapeutics, Inc. (SRPT)
This section provides a real-time view of insider transactions for Sarepta Therapeutics, Inc. (SRPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sarepta Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sarepta Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 01
2024
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
1,846
+7.48%
|
-
|
Mar 01
2024
|
Stephen Mayo |
BUY
Grant, award, or other acquisition
|
Direct |
1,846
+15.91%
|
-
|
Mar 01
2024
|
Claude Nicaise |
BUY
Grant, award, or other acquisition
|
Direct |
1,846
+9.22%
|
-
|
Dec 01
2023
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,682
-13.86%
|
$294,560
$80.34 P/Share
|
Nov 17
2023
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,508
-6.42%
|
$369,656
$82.98 P/Share
|
Nov 03
2023
|
M Kathleen Behrens |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+7.9%
|
$435,000
$29.03 P/Share
|
Nov 03
2023
|
Douglas S Ingram President & CEO |
BUY
Open market or private purchase
|
Direct |
25,225
+1.61%
|
$1,992,775
$79.97 P/Share
|
Nov 03
2023
|
Richard Barry |
BUY
Open market or private purchase
|
Indirect |
50,000
+36.11%
|
$3,900,000
$78.81 P/Share
|
Aug 14
2023
|
Michael Andrew Chambers |
BUY
Open market or private purchase
|
Indirect |
9,979
+2.0%
|
$1,087,711
$109.54 P/Share
|
Aug 11
2023
|
Michael Andrew Chambers |
BUY
Open market or private purchase
|
Indirect |
23,686
+9.09%
|
$2,558,088
$108.05 P/Share
|
Aug 10
2023
|
Michael Andrew Chambers |
BUY
Open market or private purchase
|
Indirect |
34,867
+4.9%
|
$3,661,035
$105.61 P/Share
|
Aug 04
2023
|
Hans Lennart Rudolf Wigzell |
SELL
Open market or private sale
|
Direct |
15,000
-41.67%
|
$1,590,000
$106.72 P/Share
|
Aug 04
2023
|
Hans Lennart Rudolf Wigzell |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+29.42%
|
$435,000
$29.03 P/Share
|
Jun 01
2023
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
89
-0.32%
|
$10,947
$123.6 P/Share
|
Mar 30
2023
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
307
-1.15%
|
$41,752
$136.66 P/Share
|
Mar 08
2023
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
314
-1.16%
|
$48,042
$153.19 P/Share
|
Mar 08
2023
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
635
-2.2%
|
$97,155
$153.19 P/Share
|
Mar 08
2023
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
744
-2.1%
|
$113,832
$153.19 P/Share
|
Mar 08
2023
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
912
-1.28%
|
$139,536
$153.19 P/Share
|
Mar 06
2023
|
Stephen Mayo |
BUY
Grant, award, or other acquisition
|
Direct |
1,523
+16.15%
|
-
|
Mar 06
2023
|
Claude Nicaise |
BUY
Grant, award, or other acquisition
|
Direct |
1,523
+8.53%
|
-
|
Mar 06
2023
|
Kathryn Jean Boor |
BUY
Grant, award, or other acquisition
|
Direct |
1,523
+19.15%
|
-
|
Mar 06
2023
|
Michael Andrew Chambers |
BUY
Grant, award, or other acquisition
|
Direct |
1,523
+19.15%
|
-
|
Mar 06
2023
|
Ryan Edward Brown EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+13.51%
|
-
|
Mar 06
2023
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,325
-2.6%
|
$208,025
$157.21 P/Share
|
Mar 06
2023
|
Richard Barry |
BUY
Grant, award, or other acquisition
|
Direct |
1,523
+0.05%
|
-
|
Mar 06
2023
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+5.95%
|
-
|
Mar 06
2023
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,134
-1.67%
|
$178,038
$157.21 P/Share
|
Mar 06
2023
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
1,523
+0.94%
|
-
|
Mar 06
2023
|
Ian Michael Estepan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+11.27%
|
-
|
Mar 06
2023
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,370
-4.24%
|
$215,090
$157.21 P/Share
|
Mar 06
2023
|
Bilal Arif Chief Tech Ops Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+14.29%
|
-
|
Mar 06
2023
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
340
-0.75%
|
$53,380
$157.21 P/Share
|
Mar 06
2023
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
1,523
+6.76%
|
-
|
Mar 01
2023
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
522
-0.77%
|
$76,734
$147.57 P/Share
|
Mar 01
2023
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
378
-1.16%
|
$55,566
$147.57 P/Share
|
Mar 01
2023
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
196
-0.76%
|
$28,812
$147.57 P/Share
|
Mar 01
2023
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
252
-0.55%
|
$37,044
$147.57 P/Share
|
Dec 19
2022
|
M Kathleen Behrens |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+11.21%
|
$680,000
$34.92 P/Share
|
Nov 17
2022
|
Stephen Mayo |
SELL
Open market or private sale
|
Direct |
858
-11.84%
|
$93,522
$109.92 P/Share
|
Nov 17
2022
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,211
-5.83%
|
$454,788
$108.52 P/Share
|
Sep 14
2022
|
Michael Andrew Chambers |
BUY
Open market or private purchase
|
Direct |
57,100
+16.89%
|
$5,938,400
$104.57 P/Share
|
Aug 19
2022
|
Michael Andrew Chambers |
BUY
Open market or private purchase
|
Direct |
46,170
+28.86%
|
$4,986,360
$108.5 P/Share
|
Jun 02
2022
|
Michael Andrew Chambers |
BUY
Grant, award, or other acquisition
|
Direct |
4,908
+50.0%
|
-
|
Jun 02
2022
|
Kathryn Jean Boor |
BUY
Grant, award, or other acquisition
|
Direct |
4,908
+50.0%
|
-
|
Jun 01
2022
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
54
-0.21%
|
$3,888
$72.67 P/Share
|
Mar 07
2022
|
Stephen Mayo |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+28.96%
|
-
|
Mar 07
2022
|
Richard Barry |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+0.1%
|
-
|
Mar 07
2022
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+2.09%
|
-
|
Mar 07
2022
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+13.17%
|
-
|